Altogether, the ability of RAR and PPAR stimulation to affect Aβ accumulation suggests that compounds with broad agonist activity toward RARα, RXRα, and PPAR-α and -γ could represent useful pharmacological tools to provide novel inroads for the treatment of neurodegenerative diseases. This evidence concerns the gene PPARA and neurodegenerative disease.